Healthcare - Biotechnology - NASDAQ - US
$ 4.31
-8.69 %
$ 304 M
Market Cap
-2.52
P/E
CASH FLOW STATEMENT
-107 M
OPERATING CASH FLOW
158 M
INVESTING CASH FLOW
45.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
C4 Therapeutics, Inc.
| Net Income | -132 M |
| Depreciation & Amortization | 1.88 M |
| Capital Expenditures | -1.71 M |
| Stock-Based Compensation | 27.2 M |
| Change in Working Capital | -6.94 M |
| Others | 6.59 M |
| Free Cash Flow | -109 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (132.5) | (128.2) | (83.9) | (66.3) | (34.1) | (15.7) |
| Depreciation & Amortization | 1.9 | 1.7 | 1.5 | 1.6 | 1.6 | 1.3 |
| Deferred Income Tax | 0 | 0 | 1.9 | 5.6 | 0.3 | 66 K |
| Stock Based Compensation | 27.2 | 30.0 | 21.5 | 3.4 | 1.6 | 0.6 |
| Other Operating Activities | 3.5 | 7.3 | 2.1 | 1.6 | 1.1 | 2.4 |
| Change in Working Capital | (6.9) | (16.8) | (30.1) | (13.2) | 85.0 | (5.6) |
| Cash From Operations | (106.8) | (105.9) | (87.0) | (67.2) | 55.6 | (17.0) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.7) | (5.5) | (1.3) | (0.7) | (1.3) | (2.7) |
| Other Items | 160.1 | 63.9 | (188.1) | (189.9) | (0.3) | 39.6 |
| Cash From Investing Activities | 158.3 | 58.4 | (189.3) | (190.5) | (1.6) | 36.9 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (0.1) | 0 | 0 | (0.2) | 30 K | 63 K |
| Total Debt Repaid | (12.5) | 0 | 0 | 12.0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.4 | 1.1 | 1.9 | (3.4) | 0.3 | 1.9 |
| Cash From Financing Activities | 45.5 | 1.1 | 171.4 | 348.9 | 0.2 | 2.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 97.0 | (46.4) | (104.9) | 91.2 | 54.2 | 21.9 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (108.5) | (111.4) | (88.2) | (67.9) | 54.3 | (19.7) |